Market Competition and Healthcare Policy

The enactment of the Inflation Reduction Act (IRA) and the growth of state Prescription Drug Affordability Boards have raised important questions about how to improve drug affordability without curbing biopharmaceutical innovation

This paper contributes to the literature on structural modeling of online consumer search by incorporating both product position and social influence effects (e.g., product popularity) while allowing consumers to select multiple items per search and learn adaptively about their match with the platform.

To determine how policymakers interact with bioethicists, their interest in future engagement, and their motivation and hesitations to do so

Johns Hopkins University Nexus Symposium

When a Fortune 50 employer discovered it was paying 30% more for the same hospital services than its competitors, it underscored what this panel of national experts on healthcare price transparency emphasized: despite federal transparency rules, the U.S. commercial healthcare market remains a black box.

Matching Evidence to Action as States Navigate Uncharted Territory

Expert Panelists: David C. Grabowski, PhD (Harvard Medical School); R. Tamara Konetzka, PhD (University of Chicago); Anne Deutsch, RN, PhD (RTI International)

Expert Panelists: Alexander Capron, USC Law/Bioethics; (TBC) Gabriel Danovitch, UCLA David Geffen School of Medicine; Kimberly Krawiec, UVA Law; Elaine Perlman, President, Coalition to Modify NOTA and Executive Director

MIT's Amy Finkelstein and Stanford's Liran Einav present their provocative vision for replacing America's fragmented insurance system with universal, automatic coverage designed for security, equity, and simplicity.

With commercial healthcare prices remaining stubbornly opaque and variable, this session will model how price transparency policies offer employers a powerful tool to control rising healthcare costs and empower more informed purchasing decisions.